Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK
Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population
Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study
The HAS-BLED score for prediction of stroke and systemic embolism: insights from the PREvention oF thromboembolic events, European Registry in Atrial Fibrillation (PREFER in AF)